GSK Pharma net profit rises 2 percent to Rs 255 crore in Q2
GlaxoSmithKline Pharmaceuticals has recorded a 2 percent year-on-year rise in net profit to Rs 255 crore for the quarter ended September 30, 2025.
The drugmaker had posted a net profit of Rs 249 crore in the same quarter last fiscal. However, revenue from operations, declined to Rs 974 crore in the September quarter, compared to Rs 1,000 crore a year ago, the company said in a regulatory filing.
EBIDTA margins for the quarter stood at 34.4%, reflecting a growth of 250 bps, driven by improved gross margins and operating leverage. Topline degrowth for the quarter reflects seasonal disruptions, the transitory impact of GST changes and supply chain adjustments. Supply of a few brands in the General Medicines portfolio was impacted due to a fire that occurred at one of the Company’s contract manufacturing operations.
During the quarter, the General Medicines portfolio delivered competitive performance, with key promoted brands achieving market share gains and an Evolution Index (EI) greater than 100 [Source: IQVIA]. The Vaccines business saw market share expansion, driven by strong demand and continued leadership in the self-pay private market for Paediatric vaccines. The Adult vaccines business continues to see strong traction, led by the growing adoption of Shingrix (Recombinant Herpes Zoster Vaccine, Adjuvanted), even as GSK remains focused on advancing adult immunisation in India. GSK’s entry into Oncology with the launch of its specialised therapies Jemperli (Dostarlimab) and Zejula (Niraparib) have been well-received by Healthcare Professionals (HCPs). Together, these assets reinforce the Company’s commitment to bridging critical gaps in specialised cancer care in India.
Bhushan Akshikar, Managing Director, GSK India, said, “Within two months of launch, our Oncology portfolio is impacting patients by addressing a critical unmet need in gynaecological cancers in India. Together, these assets represent meaningful progress in women’s cancer care. Moving ahead, we remain focused on ensuring that cutting-edge innovative treatments are both available and accessible to those who need them the most, supported by our comprehensive patient support and financing initiatives.”
Jemperli (dostarlimab) is an immuno-oncology treatment for second-line dMMR endometrial cancer and Zejula (niraparib), is a PARP inhibitor indicated for advanced and recurrent ovarian cancer.
Next Story